ArticleScientific reports2025
Ring-finger protein RNF126 promotes prostate cancer progression via regulation of MBNL1.
Article in Scientific reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed.
- Review
- SIRT5-RNF126 coordinated regulation of METTL17 stability controls mitochondrial function and glioma progression.Cell & bioscience · 2026Article
- SMURF2 in Anticancer Therapy: Dual Role in Carcinogenesis and Theranostics.International journal of molecular sciences · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
Abstract
purposeAberrant activation/overexpression of RNF126 is implicated as a driving event in tumor progression. However, although some functions of RNF126 in prostate cancer (PCa) cell lines has been reported, more biological functions and in-depth mechanisms should be further clarified in PCa.
methodsHere, we provide evidence that RNF126 expression is elevated in human PCa tissues and cell lines, which is associated with tumor grades and prognosis. Cell proliferation was measured by the CCK8 and colony-formation assays. Cell migration was performed by Transwell and wound-healing assays. RNF126 target proteins were investigated via proteomic, co-immunoprecipitation and western blot methods. Additionally, we knock-downed MBNL1 expression to perform rescue experiments. In vivo, xenograft mice assay was used to verify the effect of RNF126 on the growth of PCa cell.
resultsHere, we showed that RNF126 was highly expressed in PCa and its higher expression was associated with worse patients' prognosis. Expression modulation of RNF126 affects PCa cells proliferation, migration, EMT and docetaxel (DTX) resistance in vitro or in vivo. Additionally, RNF126 involves in the regulation of PI3K/AKT, MEK/ERK and EMT pathways. Mechanistically, immunoprecipitation (IP) and coimmunoprecipitation (co-IP) assays indicated that RNF126 could bind to MBNL1 directly. Our data also suggested that MBNL1 was a critical downstream event in RNF126-mediated tumorigenesis and chemo-resistance and played a crucial role in driving the PI3K/AKT, MEK/ERK and EMT pathways.
conclusionTaken together, our findings reveal a novel biological and molecular functions of RNF126 and may provide a new treatment option for PCa patients.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.